54. Asparlas

Servier
(Servier)

Active ingredient: calaspargase pegol
Disease: acute lymphoblastic leukemia
Approved: Dec. 20
Peak sales: $200 million+
Company: Servier

The scoop: As Takeda eyed Shire for a massive buyout earlier this year, Shire inked a $2.4 billion deal to sell its oncology outfit to France's Servier. Now, Servier has secured FDA approval for an acute lymphoblastic leukemia (ALL) drug picked up in the buyout, Asparlas. The drug is designed to be a longer-acting version of Oncaspar, which Servier also acquired in the purchase. The FDA approved Asparlas in December to treat ALL patients aged 1 month to 21 years. A previous investor presentation from Baxalta tagged the drug as a key program that could generate more than $200 million. Baxalta merged with Shire in 2016. Shire's oncology business generated $262 million in 2017 before the company offloaded the oncology assets to Servier. — Eric Sagonowsky

54. Asparlas

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.